John Sheridan

FDA Pediatric Lupus Workshop

News press

We are excited to share that CARRA and the Pediatric Rheumatology Collaborative Study Group (PRCSG) have collaborated to initiate the convening and planning of an FDA Workshop: Accelerating Product Development for Pediatric Systemic Lupus Erythematosus (SLE). This forum provides an opportunity for the broader community to discuss ways to streamline drug development and ensure that our community’s

CARRA Announces the 2026 Community Award Winners

News press

Washington, DC, (APRIL 17, 2026) – The Childhood Arthritis and Rheumatology Research Alliance (CARRA) is proud to announce the winners of the 2026 CARRA Community Awards. The awards, which were presented at CARRA’s Annual Scientific Meeting this month, honor people who have made outstanding achievements in advancing pediatric rheumatology research and played important roles in

New Results from Long-Term Study Show Early Use of Biologics Improves Outcomes for Children with Polyarticular Juvenile Idiopathic Arthritis

News press

WASHINGTON, D.C., October 3, 2025 – There are new long-term results from a landmark study using the CARRA Registry that looks at when to start biologics in children diagnosed with Polyarticular Juvenile Idiopathic Arthritis (poly JIA) comparing the CARRA Consensus Treatment Plans (CTPs). After following nearly 300 children with poly JIA in the CARRA Registry for

Arthritis Foundation and CARRA Increase Support for Pediatric Rheumatology Research by Awarding $2 Million in Grants

News press

ATLANTA (July 14, 2025) —  In response to changes in the federal funding environment, the Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA) have increased funding for their joint grant program that supports physician-led research in pediatric rheumatology. This year, the CARRA-Arthritis Foundation Grant Program will award nearly $2 million – an

CARRA Announces Rachel Myslinski as New CEO

News press

The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has named Rachel Myslinski, MBA, as Chief Executive Officer (CEO). Myslinski is a senior executive with more than 20 years of experience in healthcare in the professional medical association, management consulting, and non-profit research foundation settings. She brings deep expertise in executive leadership, strategic planning, non-profit Board

Workshop Findings Summarize Innovative Approaches to Pediatric Juvenile Idiopathic Arthritis Treatment Development

News press

Use of Extrapolation to Support Regulatory Decision-Making Discussed (Washington, DC – August 4, 2023) – Findings from a recent stakeholder workshop on the development of therapeutics for polyarticular JIA (pJIA) were published online in the April 27, 2023 issue of Arthritis & Rheumatology. The report, “Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): Extrapolation,

CARRA Announces Mathieu Nelessen as New CEO

News press

WASHINGTON, DC, December 6, 2022 – The Childhood Arthritis and Rheumatology Research Alliance, also known as CARRA, announced the appointment of Mathieu Nelessen as Chief Executive Officer, effective January 9, 2023. The CARRA Board of Directors unanimously approved the recommendation of Mr. Nelessen by a CARRA CEO search task force, which led a three-month nationwide

CDC Awards More Than $4 Million To Support Childhood Lupus Research

News press

Lupus Advocacy Efforts Drive Research Funding for the CARRA Registry. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) announced that the U.S. Centers for Disease Control and Prevention (CDC) awarded a 5-year $4.4 million grant to a team of North American lupus experts to advance critical research on childhood lupus through the CARRA Registry. Read